drugset
drugset / Trial / NCT06840548

A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer

NCT06840548 ↗

Phase 1 Completed 20 enrolled Philogen S.p.A.
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

Phase I and multicenter study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with clear cell renal cell carcinoma.

Timeline

Start
2025-04-16
Primary completion
2025-11-28
Completion
2025-11-28

Drugs

EvaluationDrugModalityDoseRoute
Subject [68Ga]Ga-OncoCAIX Diagnostic / imaging agent — Intravenous

Indications

clear cell renal carcinoma